Shares of Johnson & Johnson had been down 0.1% in premarket buying and selling on Tuesday after the corporate stated in testimony launched upfront of a congressional listening to that it plans to ship about 20 million doses of its COVID-19 vaccine by the top of March. J&J’s still-investigational COVID-19 vaccine candidate is at the moment underneath assessment on the Meals and Drug Administration, although the federal authorities has already agreed to buy 100 million doses of the corporate’s single-dose vaccine within the first half of the yr. Executives from J&J, AstraZeneca , Pfizer Inc. , Moderna Inc. , and Novavax Inc. are anticipated to testify Tuesday in entrance of the Home Committee on Vitality & Commerce’s subcommittee on oversight and investigations in regards to the availability of COVID-19 vaccines within the U.S. J&J’s inventory is up 7.9% over the previous 12 months, whereas the S&P 500 has gained 16.1%.Market Pulse Tales are Speedy-fire, quick information bursts on shares and markets as they transfer. Go to MarketWatch.com for extra info on this information.
Learn Full Story
2021-02-23